Tumour Invasion: A New Twist on Rac-Driven Mesenchymal Migration
Elongated mesenchymal migration of cancer cells is driven by Rac1 activation mediated by the adaptor NEDD9 and the exchange factor DOCK3. A new study reports a role for the transcription factor Twist1 in inducing mesenchymal migration by relieving the suppression of NEDD9 and DOCK3 by the microRNA let-7i.
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The epithelial-mesenchymal transition (EMT) is a highly conserved and fundamental process that governs morphogenesis in multicellular organisms and is thought to promote metastatic progression of carcinomas [1] . Some key events typical of EMT are loss of the cell-cell adhesion molecule E-cadherin, gain of N-cadherin and augmented expression of certain transcription factors. EMT leads to loss of cell-cell adhesion and increased cell migration and invasion [1] . Twist1, a transcriptional regulator, induces EMT by suppression of E-cadherin [2] . A recent paper by Yang et al. [3] now reveals that Twist1 is a key regulator of elongated mesenchymal migration of cancer cells through regulation of a microRNA (miRNA) that controls signalling by the Rho-family GTPase Rac. Rho-family GTPases are key regulators of cell migration through their actions on actin assembly and actomyosin contractility. Cells can migrate as collective groups or as individual cells. Two modes of individual cell migration have been characterized in a number of systems. An elongated ('mesenchymal-like') mode is characterized by cell polarization, a requirement for extracellular proteolysis [4] , and low actomyosin contractility [5] , and is driven by the formation of membrane protrusions that result from a localized activation of the Rac GTPase [6] . Rounded 'amoeboid' modes of cell migration are driven by high levels of actomyosin contractility regulated by Rho-ROCK signalling [5, 7] or the Cdc42 GTPase [8] . In rounded moving cells, high hydrostatic forces drive cell movement resulting in membrane blebbing [9] . Interestingly, Cdc42 is capable of regulating elongated mesenchymal or rounded contractile movement via usage of different guanine nucleotide exchange factors (GEFs) [8] .
Elongated mesenchymal movement can be driven by activation of Rac1 through the GEF DOCK3 complexed with the adaptor protein NEDD9 [5] . Rac1 promotes elongation through WAVE2-mediated actin polymerization [5, 10, 11] . Furthermore, Rac1 signalling suppresses rounded movement [5, 11, 12] through decreasing actomyosin contractility [5, 12] . In an effort to identify new functions of Twist1, Yang et al. [3] screened for possible new targets with a particular focus on miRNAs. They reasoned that Twist1 cooperates with the Polycomb group protein BMI1 [2] and they selected head and neck squamous cell carcinoma (HNSCC) cell lines that would have different expression levels of the Twist1-BMI1 pairing to compare their migratory behaviour. The authors performed microarray analysis to identify which miRNAs were co-regulated by both Twist1 and BMI1 and found that these proteins co-repressed let-7i miRNA [3] . The authors confirmed that loss of let-7i induced a morphological switch into a mesenchymal program of invasion [3] , with long-lived protrusions that are typical of a Rac-driven phenotype. They went on to find that let-7i downregulated NEDD9 and DOCK3 [3] , both of which are activators of Rac and drive mesenchymal movement in several systems [3, 5, 10, 12] . Furthermore, Twist1 overexpression induced Rac1 activation in HNSCCs, as a result of increased expression of both NEDD9 and DOCK3 [3] (Figure 1) HNSCC tends to remain localized at the primary site and regional lymph nodes. Severe local tissue destruction with a low frequency of distal organ metastasis is observed in HNSCC patients [14] . To translate their observations to the clinical setting, Yang et al. [3] made the interesting observation that decreasing amounts of let-7i are present in a cohort of HNSCC patients with tumours that have invaded adjacent tissues. Yang et al. [3] find that the Twist-let-7i-NEDD9-DOCK3 axis has prognostic value for HNSCC [3] . NEDD9 had already been found to be overexpressed during human melanoma progression [15] and was found to be a marker for elongated mesenchymal motility in human melanoma samples [12] . NEDD9 has also been found to regulate cellular protrusive activity in breast cancer models [16] . All of these studies point to NEDD9 being a bona fide mesenchymal marker, a proposal that will now need to be explored in more malignancies that use mesenchymal invasion strategies.
The question that arises is how NEDD9 might function in invasion and metastasis. It is a member of the p130Cas family and has multiple partners [17] , so it is likely to have multiple roles, in addition to the regulation of Rac activation through DOCK3. Recent work has reported that NEDD9 drives elongation and mesenchymal invasion in melanoma via engagement of integrin a v b 3 and recruitment of Src kinase [12] . A key role of NEDD9-dependent Src signalling is to suppress ROCK2, which otherwise would drive high actomyosin contractility [12] (Figure 1 ) that would in turn suppress Rac-dependent mesenchymal movement [5, 10, 12] .
In the course of their experiments Yang et al. [3] describe cells with a rounded morphology. One should be careful when addressing amoeboid phenotypes as several types of amoeboid migration have been described to date [18] . In the case of cancer cells, rounded amoeboid contractile movement is characterized by intensive blebbing. Blebs form when the plasma membrane detaches focally from the underlying actin filament cortex [19] , allowing cytoplasmic flow to push the membrane outwards rapidly due to hydrostatic pressure in the cell interior. This high blebbing is regulated by Rho-ROCK signalling [7, 9] and is characterized by high levels of phosphorylated myosin light chain II (MLC) [5, 12, 13 ]. The round cells described in the study from Yang et al. [3] lack blebs and instead display short protrusions. Furthermore, the levels of Rho-GTP or phospho-MLC in these round cells are no different, or in fact lower, than in the elongated cells considered in their study [3] . It is likely that the round cells described in [3] are different from round 'amoeboid-like' migrating cells [5, [7] [8] [9] 12, 13] . Nevertheless, the authors show in very thorough manner that manipulations of Twist1 and let-7i can lead to opposite results in terms of how they regulate elongated mesenchymal migration [3] . Twist1 positively impinges on cell elongation and invasion, and let-7i suppresses it by inhibiting DOCK3 and NEDD9 expression. Another important finding in this study is the fact that suppression of let-7i promotes tumour-initiating capabilities without affecting EMT [3] . It would be interesting to assess whether NEDD9, DOCK3 and Rac1 are involved in tumour initiation or whether it is an independent biological effect derived from let-7i suppression that does not require the Rac signalling axis.
Yang et al. [3] have described how mechanisms of HNSCC dissemination rely greatly on mesenchymal invasion and its key players NEDD9, DOCK3 and Rac1 [3] , insights that could be useful in the treatment of HSNCC patients. Targeting just one invasive strategy could be an approach against malignancies that do not metastasize so readily and that only use mesenchymal migration, as in the case of HSNCC. Interestingly Yang et al. [3] did not find any correlation with let-7i expression in human metastatic HNSCC specimens, suggesting that HNSCC metastasis may depend on different mechanisms compared with In elongated mesenchymal migrating cells, Twist1 and BMI1 mediate suppression of the miRNA let-7i, which results in NEDD9 and DOCK3 overexpression in HNSCC [3] . NEDD9 overexpression promotes elongated mesenchymal motility in HNSCC [3] , melanoma [5, 12] and breast cancer [16] . NEDD9 and DOCK3 have been reported to cooperate in order to activate Rac1 and drive mesenchymal migration in HNSCC [3] and melanoma [5, 10, 12] . WAVE2, acting downstream of Rac, drives mesenchymal migration by promoting actin assembly to form cellular protrusions in melanoma [5, 10] , glioblastoma [11] and fibrosarcoma [11] . In melanoma cells, NEDD9 acts through integrin b3 and Src to promote mesenchymal migration, as Src inhibits ROCK2-dependent rounded amoeboid invasion [12] . Cdc42 activation controls elongated mesenchymal migration in melanoma [8] via an unknown guanine nucleotide exchange factor (GEF).
HNSCC local invasion. Tumours like melanomas, which are highly metastatic [20] , may use both elongated mesenchymal and rounded amoeboid-like contractile invasion strategies in order to disseminate more efficiently. This plasticity could allow the tumour cell to cope with different environments using a larger repertoire of invasive strategies. Following this line of argument, melanoma patients should be treated with a combination of drugs that inhibit both rounded amoeboid and elongated mesenchymal types of movement [5, 7, 8, 12] . Other tumour types, such as glioblastomas and fibrosarcomas, have been reported to show similar plasticity [11] ; therefore, blocking both strategies would also be necessary in order to stop their invasion and/or metastasis [11] . The challenge for the next few years will be to validate tumour invasion signatures as prognosis markers and to find good therapeutic targets within such signatures.
